Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.

Authors

null

Gennady Bratslavsky

SUNY Upstate Medical University, Syracuse, NY

Gennady Bratslavsky , Andrea Necchi , Philippe E. Spiess , Petros Grivas , Joseph M Jacob , Oleksandr Kravtsov , Richard S.P. Huang , Vamsi Parini , Brennan Decker , Douglas I. Lin , Dean C. Pavlick , Natalie Danziger , Jeffrey S. Ross

Organizations

SUNY Upstate Medical University, Syracuse, NY, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy, Moffitt Cancer Center & Research Institute, Tampa, FL, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, SUNY Upstate Medical University, Department of Urology, Syracuse, NY, Foundation Medicine, Inc, Cambridge, MA, Foundation Medicine, Cambridge, MA, Foundation Medicine, Inc., Cambridge, MA

Research Funding

Pharmaceutical/Biotech Company

Background: FLCN is a tumor suppressor gene associated with cutaneous hair follicle development. FLCN germline mutations are linked to inherited chrRCC in the Birt-Hogg-Dube (BHD) syndrome. We queried whether clinically sporadic chrRCC featured FLCN mutations by comparing the genomic profiles of chrRCC with ccRCC. Methods: 108 chrRCC and 2110 ccRCC underwent hybrid-capture based comprehensive genomic profiling (CGP) to evaluate all classes of genomic alterations (GA). Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. PD-L1 expression was determined by IHC (Dako 22C3). Results: Patients (pts) with chrRCC were more frequently female and younger than pts with ccRCC p <.0001). None of the submitted clinical records in the chrRCC cases listed signs of BHD syndrome. FLCN GA were identified in only 2.3% of the ccRCC cases with 37% of the GA predicted to be germline. chrRCC did not reveal somatic or germline FLCN GA. GA/tumor were slightly higher in ccRCC vs chrRCC (3.6 vs 2.4; NS). GA more frequent in chrRCC included TP53, RB1 and PTEN. GA more frequent in the ccRCC included VHL, BAP1, PBRM1, SETD2, CDKN2A/B, ARID1A, NF2, PIK3CA and TERT. Putative biomarkers of immune checkpoint inhibitor (ICPI) response were infrequent in both groups with only a slightly higher, but still low, mean TMB in ccRCC vs chrRCC cases. IHC revealed moderate PD-L1 expression at low and minimal PD-L1 expression at high staining level, which was slightly increased in the chrRCC group. Conclusions:FLCN mutations that are associated with the familial incidence of chrRCC were not associated with sporadic chrRCC. Sporadic chrRCC has substantially different genomic profile from ccRCC and may harbor a few ‘targetable’ GA. The prediction of response to ICPI in RCC remains challenging with chrRCC featuring slightly higher PD-L1 expression and ccRCC featuring higher PBRM1 GA and higher TMB.


chrRCC (108 cases)
ccRCC 2110 cases)
P Value
FLCN
0% (0% germline)
2.3% (37% germline)
NS
TP53
64.8%
18.5%
<.0001
VHL
6.5%
47.4%
<.0001
PBRM1
2.8%
24.8%
<.0001
CDKN2A/B
3.7%/1.9%
25.8%/19.7%
<.0001
PTEN
21.3%
9.7%
=.0005
NF2
0%
10.5%
<.0001
PIK3CA
0%
4.9%
=.009
Mean TMB
1.8
3.3
<.0001

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 292)

DOI

10.1200/JCO.2022.40.6_suppl.292

Abstract #

292

Poster Bd #

L1

Abstract Disclosures

Similar Abstracts

Abstract

2022 ASCO Genitourinary Cancers Symposium

Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.

First Author: Petros Grivas

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.

First Author: Gentry Teng King

First Author: Antonio Cigliola